Commercial Insurance vs. Medicare vs. Medicaid: How GLP-1 Coverage Differs

One of the most important things to understand about GLP-1 coverage is that the rules are completely different depending on what type of insurance you have. A Wegovy prescription covered under one patient's Blue Cross plan may be categorically excluded under another patient's Medicare coverage — and a Medicaid patient in one state may have access that a Medicaid patient in the next state doesn't.

This isn't intuitive, and it catches a lot of people off guard. If you're used to thinking of insurance as insurance, the distinctions here matter a great deal.

Commercial Insurance (Employer and Marketplace Plans)

Commercial insurance is the coverage most working-age Americans have — either through an employer, a spouse's employer, or a plan purchased through the Affordable Care Act (ACA) marketplace.

What the coverage landscape looks like

Commercial plans have more flexibility to cover — or not cover — obesity medications. As of the mid-2020s, many commercial plans have added GLP-1 obesity medications to their formularies, though typically with prior authorization requirements, step therapy, and other restrictions. Others have excluded them entirely, citing cost.

Whether your commercial plan covers GLP-1s depends on:

Your specific plan (not just your insurance company — two Blue Cross plans can have different benefits)
Whether your employer chose to include or exclude obesity drugs (for employer-sponsored plans)
Which medications are on that plan's formulary and at what tier

How prior authorization typically works with commercial coverage

Commercial plans that cover GLP-1s almost always require prior authorization. The clinical criteria typically look for:

BMI ≥ 30, or BMI ≥ 27 with a weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea)
Documentation of prior lifestyle interventions
Occasionally, a previous trial of another weight-loss medication

The specific criteria vary by plan. Your doctor's office submits the PA and knows what's needed.

Copay savings cards and manufacturer programs

One important advantage of commercial coverage — even partial coverage — is that drug manufacturers offer copay assistance cards for patients with commercial insurance. These cards reduce out-of-pocket costs at the pharmacy. They are generally not available to Medicare or Medicaid beneficiaries.

If you have commercial insurance and are struggling with out-of-pocket costs for a covered GLP-1, ask your doctor's office about manufacturer savings programs.

Medicare

Medicare is the federal health program primarily for Americans 65 and older, as well as people with certain disabilities.

The historical coverage gap

For most of its history, Medicare has not covered obesity medications. Part D — Medicare's prescription drug benefit — has explicitly excluded "drugs used for anorexia, weight loss, or weight gain" as a category. This means that even after Wegovy and Zepbound received FDA approval, Medicare beneficiaries generally could not get them covered for the obesity indication.

This is a significant gap. Obesity is highly prevalent in the Medicare-eligible population, and many of these patients have related conditions — cardiovascular disease, type 2 diabetes, sleep apnea — where treating obesity is medically important.

What changed: cardiovascular indication

In 2024, the FDA approved semaglutide (Wegovy) for cardiovascular risk reduction in patients with established cardiovascular disease and obesity or overweight. Following this approval, CMS (the agency that runs Medicare) determined that Medicare Part D plans must cover Wegovy for this indication — because it's now classified as a cardiovascular drug, not just a weight-loss drug.

This was a meaningful expansion, but it's not universal. To qualify under this pathway:

You must have established cardiovascular disease (history of heart attack, stroke, or peripheral arterial disease)
Your BMI must meet the threshold (≥ 27 for this indication)
Your Part D plan must cover Wegovy (coverage varies by specific plan)

If you have Medicare and these conditions, ask your doctor whether you might qualify under the cardiovascular indication.

What's still not covered for most Medicare patients

As of 2026, Medicare still does not broadly cover GLP-1 medications solely for the purpose of treating obesity, for patients who don't have the specific cardiovascular qualifications above. Legislative proposals to expand coverage have been introduced in Congress, and this is a fast-moving policy area — but full obesity medication coverage under Medicare has not yet been enacted.

Medicare Advantage plans

Medicare Advantage (Part C) plans — private insurance alternatives to traditional Medicare — have more flexibility in their benefits. Some Medicare Advantage plans have added obesity medication coverage as a supplemental benefit, and this varies by plan and geography. If you have Medicare Advantage, check your plan's formulary specifically.

Manufacturer programs and Medicare

Federal anti-kickback laws prohibit most drug manufacturers from offering copay assistance cards to Medicare beneficiaries. Patient assistance programs (income-based free medication programs) may be available — check the manufacturer's website or ask your doctor's office.

Medicaid

Medicaid is the joint federal-state health program for people with low incomes. Each state runs its own Medicaid program within federal guidelines, which creates enormous variation in what's covered.

Coverage varies dramatically by state

Some state Medicaid programs cover GLP-1 medications for obesity. Others exclude them. Others cover some GLP-1s but not others. There is no national rule that requires Medicaid to cover these medications for the obesity indication.

States that have chosen to cover these medications typically have prior authorization requirements with clinical criteria similar to commercial plans. States that have not covered them may still cover GLP-1s for type 2 diabetes management under their pharmacy benefits.

How to find out what your state Medicaid covers

Contact your state Medicaid office directly. Each state has a Medicaid agency; the phone number is usually on your Medicaid card.
Ask your doctor's office. Obesity medicine and primary care practices that treat Medicaid patients will often know the current policies for your state.
Check the Medicaid formulary for your state. Many states publish these online through their Medicaid program websites.

Managed care plans within Medicaid

Many states administer Medicaid through managed care organizations (MCOs) — essentially private insurance companies contracted to manage Medicaid benefits. If you're in a Medicaid managed care plan, your MCO may have its own formulary and prior authorization policies within what the state allows. Your MCO's formulary is the document you need to consult.

Dual eligibles (Medicare + Medicaid)

If you have both Medicare and Medicaid (sometimes called "dual eligibles"), your prescription drug coverage is typically handled through a specialized plan. The rules for these plans can be complex. Talk to your care coordinator or a State Health Insurance Assistance Program (SHIP) counselor about what obesity medication coverage looks like in your situation.

Quick Comparison at a Glance

| | Commercial Insurance | Medicare | Medicaid | |---|---|---|---| | General GLP-1 coverage for obesity | Varies by plan; many cover with PA | Generally not covered (exceptions for cardiovascular indication) | Varies by state | | Prior authorization required? | Almost always when covered | Required when covered | Yes, if covered | | Manufacturer copay cards available? | Yes (for most) | No (federal law restriction) | No (federal law restriction) | | Coverage determined by | Employer + insurer | Federal CMS rules + Part D plans | State + MCO | | Step therapy common? | Yes | Depends on plan | Varies by state |

The Bottom Line

Your insurance type shapes your GLP-1 coverage situation more than almost any other factor. Commercial insurance patients have the most pathways open, though still face PA hurdles and frequent exclusions. Medicare patients face significant gaps unless they have qualifying cardiovascular disease. Medicaid patients face a patchwork of state-by-state policies.

Knowing which type of insurance you have — and understanding that the rules are specific to that type — is the starting point for figuring out your options. Your doctor's office and your insurance company's member services line are the best sources for the specifics of your situation.

For guidance on choosing a better plan at open enrollment, see Open Enrollment: How to Pick a Plan That Covers Your Medication.